TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06569069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US guided PE
Description: The multifidus muscle near the posterior dorsal root (at L4-L5 or L5-S1) was targeted using a transverse ultrasound view, inserting the needle at an 80º short axis or a 45º long axis, based on vessel presence. For the tibial nerve in the popliteal region, the needle was inserted at an 80º angle after a transverse cut of the nerve.~Physio invasiva® needles (0.30 x 40-60 mm) were used in the lumbar region, and 0.30 x 30 mm needles in the popliteal region. Both areas received galvanic current (1.5 mA for three seconds and three impacts). Treatment included three US-guided PE sessions over a 1:7:14 schedule, though two participants skipped the third due to pain resolution.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Participants in the control group were also treated in a prone position. Sham acupuncture treatment was applied at the superficial level of the posterior face of the thigh on the affected side, using five Agupunt® needles of 0.16 x 25 mm, inserted superficially in the lateral aspect of the lumbar area (L3-L4), lateral gluteal region, greater trochanter, lateral part of the distal third of the thigh, head of the fibula and lateral aspect of the leg in its middle third. The needles were left superficially subcutaneously for 15 minutes, performing this approach in three different sessions, again following a periodicity of 1:7:14 days.
Study: NCT06540586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior Quadratus lumborum block
Description: Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 25 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior Quadratus lumborum block
Description: Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 25 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
Study: NCT04777409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
Study: NCT06211647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-XT117
Description: \[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at fixed dose levels at an interval of 6 weeks between each dose.
Study: NCT06139952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: Atorvastatin 80mg taken Once before coronary angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: Atorvastatin 80mg taken Once before coronary angiography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: 200mg 3 times daily 2 days before coronary angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: 200mg 3 times daily 2 days before coronary angiography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: adequate hydration using Normal Saline (1ml/kg/hr)
Study: NCT05566340

Intervention type: PROCEDURE
Intervention: mitral valve repair
Description: Repair of mitral valve concomitant to aortic valve replacement.

Intervention type: PROCEDURE
Intervention: mitral valve repair
Description: Repair of mitral valve concomitant to aortic valve replacement.
Study: NCT05510297

Intervention type: DEVICE
Group type: OTHER
Intervention: FitSitt Prototype
Description: FitSitt merges features of a posture chair, exercise machine, and tracking means. It provides seated stepping, postural support, and semi-recline capabilities. A digital interface and app will allow users to set goals and track performance.
Study: NCT06250101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Conversational Recast treatment
Description: In the context of child-friendly activities, the clinician prompts the child to attempt to use the grammatical form targeted in the treatment. The clinician immediately restates the child's attempt (i.e., the recast), correcting any ungrammatical elements. Clinicians elicit and recasts 24 utterances per session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Conversational Recast treatment
Description: In the context of child-friendly activities, the clinician prompts the child to attempt to use the grammatical form targeted in the treatment. The clinician immediately restates the child's attempt (i.e., the recast), correcting any ungrammatical elements. Clinicians elicit and recasts 24 utterances per session.
Study: NCT06243497

Intervention type: PROCEDURE
Intervention: Ultrasound CycloPlasty
Description: All procedures were performed using the EyeOP1 device . The coupling cone was placed and adjusted on the centre of the patient's eye by visualising an equal white scleral ring surrounding the cornea. The coupling cone was kept in place via vacuum suction activated using a foot pedal and was then filled with a balanced salt solution to allow ultrasound transmission. The transducers were automatically activated at a frequency of 21 MHz and an acoustic power of 2.45 W, with an 8-s duration for each sector and a 20-s pause between each treatment to allow complete evacuation of heat.
Study: NCT05950204

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)
Description: Intervention with 100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks. The other group of patients will receive only the same dose of VD and calcium.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)
Description: Intervention with 100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks. The other group of patients will receive only the same dose of VD and calcium.
Study: NCT04717934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAL1906
Description: hyaluronic acid dermal filler gel
Study: NCT05388526

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention to be administered, only collection of data through various tests and questionnaires.
Study: NCT04761523

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention: reduced fat diet
Description: Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
Study: NCT06467526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Oral hydroxychloroquine (400mg/day) for 2 months

Intervention type: DRUG
Group type: OTHER
Intervention: Steroid
Description: Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid
Description: Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)
Study: NCT04761523

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention: standard healthy diet
Description: Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
Study: NCT06203405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titrating sedation targeting both optimal P0.1 and appropriate arousal level
Description: * Sedation will be adjusted initially to target light sedation (RASS 0 to -2).~* Sedative drugs include IV fentanyl (25-75 mcg/h), midazolam (0.02- 0.1 mg/kg/h), propofol (5-50 mcg/kg/min), dexmedetomidine (0.2-0.7 mcg/kg/h).~* Deep sedation and neuromuscular blocking agents are allowed to facilitate mechanical ventilation adjustment in patients with refractory hypoxemia.~* Dose of cisatracurium is 0.15-0.2 mg/kg intravenous bolus, then continuous infusion at 5 -20 mg/h.~* Then sedation adjustment will be guided by P0.1 measurement.~* If P0.1 value of 1.5-3.5 cmH2O is achieved, no further adjustment is required.~* If P0.1 value \<1.5, sedation will be reduced.~* If P0.1 value \>3.5, sedation will be increased.~* If P0.1 value is still \>3.5 with deep sedation, cisatracurium will be allowed and titrated until P0.1 value \<3.5 cmH2O.~* The study protocol will be continued for 48 hours or until the patients are considered ready for weaning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Continuous intravenous infusion of fentanyl 25-75 micrograms/hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Continuous intravenous infusion of midazolam 0.02 - 0.1 milligrams/kilogram/hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Continuous intravenous infusion of propofol 5 - 50 micrograms/kilogram/minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continuous intravenous infusion of dexmedetomidine 0.2 - 0.7 micrograms/kilogram/hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Continuous intravenous infusion of cisatracurium 5 - 20 milligrams/hour
Study: NCT05832034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human)
Description: IVIg is 2 g/kg over 2 to 5 days at baseline, followed by 2 g/kg IV in 2 to 5 days after 4 and 8 weeks. The rate of infusion is controlled by means of an infusion pump. The first dosage (30 grams IVIg) will be administered on the neurology ward.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks.
Study: NCT04762212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with movement and stretching, stretching or control
Description: The participants will receive a therapist performed mobilization with movement and then instructed in a stretching program to be followed for one week or only receive instruction in a stretching program to be followed for one week on the hip with the greatest limitation in motion. The hip with the least amount of limitation will not receive an intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with movement and stretching, stretching or control
Description: The participants will receive a therapist performed mobilization with movement and then instructed in a stretching program to be followed for one week or only receive instruction in a stretching program to be followed for one week on the hip with the greatest limitation in motion. The hip with the least amount of limitation will not receive an intervention.
Study: NCT06054672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subthreshold Electrical stimulation
Description: We will use a electrotherapy device to deliver subthreshold Electrical stimulation
Study: NCT04852094

Intervention type: OTHER
Intervention: Qualitative focus group
Description: A qualitative focus group is performed with staff members and parents of hospitalised newborns in a NICU during Family-centered rounds management. The transcribed interviews are analyzed with qualitative content analysis in order to illuminate the experience, feelings and thoughts arisen among the staff members and the parents.

Intervention type: OTHER
Intervention: Qualitative focus group
Description: A qualitative focus group is performed with staff members and parents of hospitalised newborns in a NICU during Family-centered rounds management. The transcribed interviews are analyzed with qualitative content analysis in order to illuminate the experience, feelings and thoughts arisen among the staff members and the parents.
Study: NCT05448664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family HBM- mobile messaging
Description: The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students and their parents in the following 24 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent HBM- mobile messaging
Description: The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students in the following 24 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Adolescent e-pamphlets
Description: The contents of e-version of three pamphlets, published by Department of Health (http://www.toothclub.gov.hk/en/en_index.html) will be distributed in an electronic form and sent via a mobile message.
Study: NCT05910762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Associative inference
Description: Participants will engage in an associative inference paradigm. Memory will be assessed behaviorally and neural representations will be assessed using functional magnetic resonance imaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Category learning
Description: Participants will engage in a category learning paradigm. Memory will be assessed behaviorally (Arms 2 and 3), and neural representations will be assessed using functional magnetic resonance imaging (Arm 2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Category learning
Description: Participants will engage in a category learning paradigm. Memory will be assessed behaviorally (Arms 2 and 3), and neural representations will be assessed using functional magnetic resonance imaging (Arm 2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep
Description: Participants will sleep after engaging in a category learning paradigm while electroencephalography data are collected, and memory will be assessed behaviorally after sleep.
Study: NCT06085898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stryphnodendron Adstringens 3% - once daily post bath
Description: Intimate Soap
Study: NCT06387303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Intravenous Methadone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intrathecal Morphine
Study: NCT06426797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab plus anlotinib
Description: cadonilimab (10mg/Kg, ivgtt, d1) and anlotinib (12mg, P.O., d1-d14) on a 21-day regimen for 3 cycles
Study: NCT05131893

Intervention type: DRUG
Intervention: Tamoxifen
Description: endocrine therapy

Intervention type: DRUG
Intervention: Tamoxifen
Description: endocrine therapy

Intervention type: DRUG
Intervention: Tamoxifen
Description: endocrine therapy

Intervention type: DRUG
Intervention: Goserelin
Description: endocrine therapy

Intervention type: DRUG
Intervention: Goserelin
Description: endocrine therapy

Intervention type: DRUG
Intervention: Goserelin
Description: endocrine therapy

Intervention type: DRUG
Intervention: Letrozole 2.5Mg Tab
Description: endocrine therapy

Intervention type: DRUG
Intervention: Letrozole 2.5Mg Tab
Description: endocrine therapy

Intervention type: DRUG
Intervention: Letrozole 2.5Mg Tab
Description: endocrine therapy

Intervention type: DRUG
Intervention: Epirubicin
Description: chemotherapy
Study: NCT04824534

Intervention type: OTHER
Intervention: Motion analysis
Description: Motion analysis is performed in the Motionlab using Vicon systems. Surgery (in case of SI patients) is performed with iFuse implant system for sacroiliac joint fusion

Intervention type: OTHER
Intervention: Motion analysis
Description: Motion analysis is performed in the Motionlab using Vicon systems. Surgery (in case of SI patients) is performed with iFuse implant system for sacroiliac joint fusion

Intervention type: OTHER
Intervention: Motion analysis
Description: Motion analysis is performed in the Motionlab using Vicon systems. Surgery (in case of SI patients) is performed with iFuse implant system for sacroiliac joint fusion
Study: NCT05131893

Intervention type: DRUG
Intervention: Epirubicin
Description: chemotherapy

Intervention type: DRUG
Intervention: Epirubicin
Description: chemotherapy

Intervention type: DRUG
Intervention: cyclophosphamide
Description: chemotherapy
Study: NCT04839081

Intervention type: OTHER
Intervention: questionnaires and inventories
Description: questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.

Intervention type: OTHER
Intervention: questionnaires and inventories
Description: questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
Study: NCT05545852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)
Description: Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COT(Conventional Open Thyroidectomy)
Description: Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
Study: NCT06454981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodiafilter
Description: The enrolled patients were randomly divided into the experimental group and the control group, using the hemodiafilter (experimental device) produced by Shinva Medical Instrument Co.,Ltd.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fresenius Medical Care AG & Co.KGaA
Description: The enrolled patients were randomly divided into the experimental group and the control group, using the FX 800HDF hollow fiber hemodialysis/filter (control device) produced by Fresenius Medical Care AG \& Co.KGaA (registered agent: Fresenius Medical Care (shanghai) Company Limted).
Study: NCT06245070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Description: HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Active stimulations will be delivered by a 9 MxN Soterix HD-tES device for 20 minutes( 2 mA) per day for 5 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct current stimulation
Description: HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Sham stimulations will be delivered by a 9 MxN Soterix HD-tES device. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
Study: NCT06531603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine wound infilteration
Description: drug was given at the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus dexmedetomidine wound infilteration
Description: drug was given at the end of surgery
Study: NCT05131893

Intervention type: DRUG
Intervention: cyclophosphamide
Description: chemotherapy

Intervention type: DRUG
Intervention: cyclophosphamide
Description: chemotherapy

Intervention type: DRUG
Intervention: Docetaxel
Description: chemotherapy
Study: NCT05866094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Nutrition training will be provided to home care staff to deliver the intervention via the participating Home Care Providers from two localities (South and North of England).~This phase will involve identification of people with dementia on their caseload, preliminary assessment of potential impact via collection of quantitative data at baseline (pre-intervention), and at 4 months follow-up (4 months after the first visit by trained home care workers, following baseline).~A process evaluation will be conducted to gather data on intervention fidelity and implementation (quantitative and qualitative).